Review findings

des for skin health — GHK-Cu, SNAP-8, Melanotan-1, BPC-157, and Glutathione reviewed with evidence levels and mechanisms of action.

des for skin health — GHK-Cu, SNAP-8, Melanotan-1, BPC-157, and Glutathione reviewed with evidence levels and mechanisms of action.

des for skin health — GHK-Cu, SNAP-8, Melanotan-1, BPC-157, and Glutathione reviewed with evidence levels and mechanisms of action.

des for skin health — GHK-Cu, SNAP-8, Melanotan-1, BPC-157, and Glutathione reviewed with evidence levels and mechanisms of action.

Restore access No thanks, continue reading Related Reading Peptide Melanotan-2 melanocortin receptor agonist Peptide PT-141 bremelanotide melanocortin agonist Comparison Melanotan-1 vs Melanotan-2: Tanning Peptides Compared How Melanotan-1 works at the cellular level Overview of Melanotan-1 benefits and applications Scientific Details Molecular Formula C78H111N21O19 Molecular Weight 1646.85 Da CAS Number 75921-69-6 Sequence Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 What is Melanotan-1? # Melanotan-1 is a peptide that has been studied in preclinical and clinical research models for its potential therapeutic properties.

Peptide Protocol Wiki February 10, 2026 Melanotan-2 Melanotan-1 PT-141 + 1 more Guide 11 min read 8 Peptides for Skin Health and Rejuvenation: Research Guide Pepti

Reproductive Health Skin & Hair PT-141 PT-141 (Bremelanotide): FDA-approved for hypoactive sexual desire.

16 mg implant every 2 months (approved) Frequency Daily for 10 days per cycle (injection); every 2 months (implant) Duration 10-day injection cycles repeated monthly for 3 months; or 3-4 implants per year seasonally 💊 Administration Route SC Schedule Daily for 10 days per cycle (injection); every 2 months (implant) Timing No specific timing; implant insertion by specialist physician 📅 Cycle Duration 10-day injection cycles repeated monthly for 3 months; or 3-4 implants per year seasonally Repeatable Yes Course-based protocol with rest periods Preparation & Storage Diluent: Sterile water ⚗️ Suggested Bloodwork ( 3 tests) CMP with liver enzymes When: Baseline Why: Baseline metabolic function CBC When: Baseline Why: Baseline blood counts Liver enzymes When: 3 months Why: Monitor hepatic function 💡 Key Considerations → SC injection bioavailability is approximately 100% relative to IV → Half-life is approximately 1.3 hours after SC injection → Contraindication: Avoid in melanoma or history of melanoma; use with caution in patients with many atypical nevi Subscribe to unlock this content Get weekly peptide research summaries, new study alerts, and protocol updates — free.

dose: 16 mg · cycle: cycle · route: IV · duration: for 10 days · frequency: Daily · reconstitution: Sterile water

30 (EP004); other small cohorts NR SC or IV bolus dosing in early trials (e.g., 0.08–0.16 mg/kg daily ×10) and implant doses 5–40 mg; marketed implant 16 mg PK parameters; pigmentation induction and duration; dose–response for pigmentation Plasma β-phase half-life ≈ 1.07–1.3 h after IV/SC; pigmentation onset ~week 2, maximal weeks 3–5, fading by ~week 9 after short courses; implants p...

dose: 0.16 mg · route: IV · frequency: daily

EPP (US RCT, NEJM 2015) Randomized, placebo-controlled, US phase 3 (Langendonk et al.) 89 (46 treated, 43 placebo) 16 mg subcutaneous implant; three implants over 6 months Hours in direct sunlight (10:00–18:00) without pain; phototoxic episodes; diary no-pain days Median hours: 69.4 (treated) vs 40.8 (placebo);

dose: 16 mg · route: subcutaneous

Early EPP photoprovocation open-label First open photoprovocation / pilot in EPP (small, early study) 5 patients (pilot) 20 mg subcutaneous slow-release implant ×2 doses (60 days apart) Time to intolerable pain on artificial white-light provocation ~11-fold increase in time to intolerable pain after two implants (pilot data) Safety data limited in pilot; no major safety signals reported in this small open study Safety / PK (early healthy-volunteer and implant escalation) Early human pharmacology, dose-finding and implant PK studies (multiple early-phase trials) Dose-escalation implant study example: n ≈

dose: 20 mg · route: subcutaneous

Vitiligo (JAMA Dermatology 2015 RCT) Randomized multicenter trial: afamelanotide implants + NB-UVB vs NB-UVB alone (Lim et al.) ITT n = 55 (combination ~27, NB-UVB ~26) Four monthly 16 mg subcutaneous implants (days 28,56,84,112) + NB-UVB 2–3x/wk vs NB-UVB alone for up to 6 months Repigmentation (VASI and time-to-onset); safety during combination therapy Mean relative VASI improvement at day 168: 48.64% (95% CI 39.49–57.80) combination vs 33.26% (95% CI 24.18–42.33) NB-UVB;

dose: 16 mg · route: subcutaneous

16 mg subcutaneous implant; five implants over 9 months (~every 60 days) Hours in direct sunlight (10:00–15:00) without pain; phototoxic reactions;

dose: 16 mg · route: subcutaneous

It is administered as a 16 mg subcutaneous, controlled‑release implant, typically every ~60 days.

dose: 16 mg · route: subcutaneous

Quick-Reference Photoprotection and skin tanning via MC1R agonism (approved as afamelanotide for EPP) 💉 Dosing Amount 0.16 mg/kg daily (injection protocol);

dose: 0.16 mg · frequency: daily

Other dermatologic photoprotection contexts and early studies • Early EPP photoprovocation pilot (two 20 mg implants, 60 days apart) reported ~11‑fold increases in time to intolerable pain under artificial white light. • Reviews summarize small studies in solar urticaria and polymorphic light eruption exploring systemic photoprotection with afamelanotide; broader prevention themes note the need for larger trials.

dose: 20 mg

PBTT cohort n=39 (3-year follow-up) Typically 16 mg implants every ~60 days (real-world sometimes 5–6 implants/year) Sustained increases in light exposure and QoL;

dose: 16 mg

2,933 LFTs and 1,186 PPIX measures analyzed Historically 20 mg implants (early) then 16 mg (SCENESSE®) at ~60-day intervals; real-world dosing varied Associations between afamelanotide dosing and liver tests / PPIX concentrations PPIX increased significantly with longer interval since last implant (p 0.0001);

dose: 20 mg

Melanotan-2 remains a research compound with significant safety concerns and no approved indications → Related Articles Research Review 11 min read Melanotan Tanning Peptides: Risks and Research Evidence Melanotan-1 and Melanotan-2 tanning peptide review — how they work, documented risks including mole changes, side effects, and legal status.

Start the 7-step beginner guide Peptides Side Effects New Directory Learn Tools Blog News About Melanotan-1 📋 Overview 🧬 Molecule 🔄 Similar ⚠️ Side Effects 💉 Dosing 🔬 Research 🚨 Risks 👥 Community 📊 Community Data Home Peptides Melanotan-1 Skin & Hair Cosmetic & Anti-Wrinkle approved Melanotan-1 Also known as: MT-1, MT1, Melanotan I, MT-I, Afamelanotide, Scenesse, NDP-alpha-MSH, CUV1647 Compare with 2 peptide s Research compiled by Peptide Protocol Wiki 📅 Updated February 1, 2026 Citations Verified TL;DR Melanotan-1 (Afamelanotide) is a synthetic 13-amino acid linear analog of alpha-melanocyte-stimulating hormone (alpha-MSH).

Browse all skin peptides → Table of Contents 📌 TL;DR • EMA-approved for erythropoietic protoporphyria (EPP) as Scenesse • Stimulates melanogenesis for enhanced photoprotection • More selective MC1R agonist compared to Melanotan-2 • Demonstrated UV protection in clinical trials Community-Reported Side Effects Anecdotal ? 📋 Protocol

Covers MC4R mechanism, Vyleesi trial data, dosing, and side effects. ⚠️ Medical Disclaimer This website is for educational and informational purposes only.

Safety showed similar erythema rates between groups, with expected hyperpigmentation in some combination‑treated patients and occasional nausea; one serious adverse event (hypertension) was reported.

The most common adverse events were transient headache, nausea, fatigue, flushing, nasopharyngitis, back pain, and expected skin hyperpigmentation.

In long‑term cohorts, ~89% experienced transient events lasting about 1–2 days, often within hours to one day after implantation; no consistent drug‑related serious adverse events were observed.

No dose-limiting toxicities in early dose-finding (no grade-2 toxicities); implant-related transient AEs; implant formulation biodegradable (PLG) EPP (observational liver-function study) Retrospective observational lab-analysis of treated EPP patients (Minder et al.

Retrospective design with possible confounding; authors report dose-dependent association with improved LFTs and lower PPIX but caution on causality Some detailed metrics (e.g., exact proportion of vitiligo patients achieving ≥50% repigmentation; numeric PBTT magnitude) were not reported in the provided excerpts and thus are summarized qualitatively.

Adverse events were mostly mild, with no serious events attributed to drug; overall profile was acceptable.

Adverse events were generally minor (nausea, fatigue, headache).

Implant‑site hyperpigmentation is common; most adverse events are mild.

Balanced assessment For EPP, the evidence base is moderate‑to‑strong: two high‑quality RCTs demonstrate clinically meaningful gains in sunlight tolerance and QoL, corroborated by prospective cohorts and PASS data with generally mild adverse events.

PMID: 32811524): PBTT median increased from 10 min to 180 min on treatment Related Reading # Melanotan-1 research studies and evidence Melanotan-1 dosing protocols Melanotan-1 side effects profile Afamelanotide research guide Bivamelagon research guide Stay current on Melanotan-1 research We summarize new studies, safety updates, and dosing insights — delivered biweekly.

What are the side effects of Melanotan-1?

Reported side effects of Melanotan-1 include nausea, headache, implant-site hyperpigmentation, flushing, nasopharyngitis.

Most reported side effects are mild and transient.

Consult the detailed side effects profile for full information.

Covers MC1R/MC4R activation, dosing protocols, side effects, and regulation.

Melanotan-1 (Afamelanotide): Skin Peptide Guide | Peptide Protocol Wiki Skip to main content 🧬 Peptide Protocol Wiki Peptides Side Effects New Learn Directory Tools Blog News About ⌘K ⌘K 🌱 New to Peptides?

Peptide Directory All Peptides Metabolic Anti-Obesity Anti-Aging Immune Hormonal View All Categories Directory Peptide Vendors Analytics Labs Side Effects Database Report a Side Effect Learn Start Here What Are Peptides?

PBTT cohort n=39 (3-year follow-up) Typically 16 mg implants every ~60 days (real-world sometimes 5–6 implants/year) Sustained increases in light exposure and QoL;

16 mg implant every 2 months (approved) Frequency Daily for 10 days per cycle (injection); every 2 months (implant) Duration 10-day injection cycles repeated monthly for 3 months; or 3-4 implants per year seasonally 💊 Administration Route SC Schedule Daily for 10 days per cycle (injection); every 2 months (implant) Timing No specific timing; implant insertion by specialist physician 📅 Cycle Duration 10-day injection cycles repeated monthly for 3 months; or 3-4 implants per year seasonally Repeatable Yes Course-based protocol with rest periods Preparation & Storage Diluent: Sterile water ⚗️ Suggested Bloodwork ( 3 tests) CMP with liver enzymes When: Baseline Why: Baseline metabolic function CBC When: Baseline Why: Baseline blood counts Liver enzymes When: 3 months Why: Monitor hepatic function 💡 Key Considerations → SC injection bioavailability is approximately 100% relative to IV → Half-life is approximately 1.3 hours after SC injection → Contraindication: Avoid in melanoma or history of melanoma; use with caution in patients with many atypical nevi Subscribe to unlock this content Get weekly peptide research summaries, new study alerts, and protocol updates — free.

Similar safety profile to EU trial; transient AEs as above; hyperpigmentation common; no clear hepatic safety signal in trials EPP (long-term observational cohorts) Multiple observational/real-world cohorts (cohort sizes and follow-up varied) Examples: 115 patients (314 patient-years); cohort of 117 patients reported elsewhere;

limited controlled long-term surveillance; need longer independent follow-up Polymorphic light eruption (PLE) Small RCTs / registered trials (some phase III), limited published results Small trials (reported trial sizes small; several completed/unpublished) Limited / inconclusive data; some trials registered but results unpublished or underpowered Reported tolerability similar to EPP data in small studies Key trials unpublished or small; evidence insufficient to establish efficacy Solar urticaria Phase II pilot studies / small open-label reports Very small pilot cohorts (e.g., n≈5 in pilot studies) Preliminary reports of symptom reduction (wheal area, tolerance) and increased melanisation Small-sample tolerability acceptable in reports Very small, uncontrolled studies; preliminary only — insufficient for practice change Vitiligo (adjunct to NB-UVB) Small randomized / pilot adjunct trials (afamelanotide + NB-UVB) Small multicenter randomized trial (reported n≈28) and pilot series Faster and deeper repigmentation reported with afamelanotide + NB-UVB vs NB-UVB alone in small study Generally well tolerated as adjunct; pigmentation contrasts may affect appearance Small N, short follow-up, adjunct setting (unclear independent effect), need larger RCTs Xeroderma pigmentosum / UV–DNA repair (mechanistic / early studies) Early-phase studies, mechanistic human photobiology studies, small trials/registries (Phase 1/2) DNA-repair volunteer study (n≈10 completed);

16 mg implant every 2 months (approved) Frequency Daily for 10 days per cycle (injection); every 2 months (implant) Duration 10-day injection cycles repeated monthly for 3 months; or 3-4 implants per year seasonally 💊 Administration Route SC Schedule Daily for 10 days per cycle (injection); every 2 months (implant) Timing No specific timing; implant insertion by specialist physician 📅 Cycle Duration 10-day injection cycles repeated monthly for 3 months; or 3-4 implants per year seasonally Repeatable Yes Course-based protocol with rest periods Preparation & Storage Diluent: Sterile water ⚗️ Suggested Bloodwork ( 3 tests) CMP with liver enzymes When: Baseline Why: Baseline metabolic function CBC When: Baseline Why: Baseline blood counts Liver enzymes When: 3 months Why: Monitor hepatic function 💡 Key Considerations → SC injection bioavailability is approximately 100% relative to IV → Half-life is approximately 1.3 hours after SC injection → Contraindication: Avoid in melanoma or history of melanoma; use with caution in patients with many atypical nevi Subscribe to unlock this content Get weekly peptide research summaries, new study alerts, and protocol updates — free.

Peptide Protocol Wiki February 10, 2026 GHK-Cu SNAP-8 Melanotan-1 + 3 more You Might Also Like Related content you may find interesting Peptide Skin Afamelanotide Peptide Skin Melanotan-2 Peptide Skin Matrixyl Peptide Skin PP405 Table of Contents What is Melanotan-1?

des for skin health — GHK-Cu, SNAP-8, Melanotan-1, BPC-157, and Glutathione reviewed with evidence levels and mechanisms of action.

des for skin health — GHK-Cu, SNAP-8, Melanotan-1, BPC-157, and Glutathione reviewed with evidence levels and mechanisms of action.

des for skin health — GHK-Cu, SNAP-8, Melanotan-1, BPC-157, and Glutathione reviewed with evidence levels and mechanisms of action.

des for skin health — GHK-Cu, SNAP-8, Melanotan-1, BPC-157, and Glutathione reviewed with evidence levels and mechanisms of action.

des for skin health — GHK-Cu, SNAP-8, Melanotan-1, BPC-157, and Glutathione reviewed with evidence levels and mechanisms of action.

des for skin health — GHK-Cu, SNAP-8, Melanotan-1, BPC-157, and Glutathione reviewed with evidence levels and mechanisms of action.